Role of hepatosteatosis in HBsAg seroconversion in HBeAg‐negative chronic hepatitis B patients
Background In chronic Hepatitis B virus (HBV) infection, certain individual and viral characteristics such as advanced age, presence of hepatic steatosis (HS), normal ALT levels, initially negative HBeAg and HBV DNA, and genotype of the virus are associated with HBsAg seroclearance and seroconversio...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2021-12, Vol.75 (12), p.e14899-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 12 |
| container_start_page | e14899 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 75 |
| creator | Bacaksız, Ferhat Gökcan, Hale Akdoğan, Meral Gökçe, Dilara Turan Arı, Derya Gökbulut, Volkan Ergün, Yakup Öztürk, Ömer Kacar, Sabite |
| description | Background
In chronic Hepatitis B virus (HBV) infection, certain individual and viral characteristics such as advanced age, presence of hepatic steatosis (HS), normal ALT levels, initially negative HBeAg and HBV DNA, and genotype of the virus are associated with HBsAg seroclearance and seroconversion. Herein, we report the results of our study evaluating the association between hepatosteatosis and HbsAg seroconversion.
Methods
The clinical and biochemical data of patients with CHB and hepatosteatosis (HS) (HBsAg seroconversion, n:52, and non‐HbsAg seroconversion, n:352), and the rate of development of HBsAg seroconversion were evaluated.
Results
We collected data from 404 patients with HBeAg negative CBH (mean age ± SD: 36.2 ± 11 years; 223 [55.2%] men, 181 [44.8%] women). The mean age at diagnosis of disease was 36.2 ± 11 years. The mean duration of the disease was 10.6 ± 7 years. Seroconversion developed in 52 patients (12.8%) with serum HBsAg positive (mean ± SD: 12.7 ± 5.8). Elderly age and the duration of disease time were significantly associated with seroconversion (P |
| doi_str_mv | 10.1111/ijcp.14899 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2575382682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2575382682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3939-171034950af420000ac50fa9c57e029c77bac79379c6da801dd40ef1206681313</originalsourceid><addsrcrecordid>eNp9kM1OGzEQxy1URID2wgNUK3GpkBY8_livjyFq-RASqGrPrnFmE0ebdWpvqLjxCDwjT4LDAgcOncN4NPr5p9GfkAOgx5DrxC_c6hhErfUW2QUlWAlMwKc886ouJeUwInspLShlUtZ0h4y4kEJBxXfJn5-hxSI0xRxXtg-px033qfBdcX6axrMiYQwudHcYkw_dsMfx7OnhscOZ7f0dFm4eQ-fd4PB9_n1abCbs-vSZbDe2Tfjl9d0nv398_zU5L6-uzy4m46vScc11CQooF1pS2whGc1knaWO1kwop006pW-uU5kq7amprCtOpoNgAo1VVAwe-T74N3lUMf9eYerP0yWHb2g7DOhkmleQ1q2qW0cMP6CKsY5evM6wCobNP1pk6GigXQ0oRG7OKfmnjvQFqNrmbTe7mJfcMf31Vrm-XOH1H34LOAAzAP9_i_X9U5uJycjNInwEz64z7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2614981358</pqid></control><display><type>article</type><title>Role of hepatosteatosis in HBsAg seroconversion in HBeAg‐negative chronic hepatitis B patients</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Bacaksız, Ferhat ; Gökcan, Hale ; Akdoğan, Meral ; Gökçe, Dilara Turan ; Arı, Derya ; Gökbulut, Volkan ; Ergün, Yakup ; Öztürk, Ömer ; Kacar, Sabite</creator><creatorcontrib>Bacaksız, Ferhat ; Gökcan, Hale ; Akdoğan, Meral ; Gökçe, Dilara Turan ; Arı, Derya ; Gökbulut, Volkan ; Ergün, Yakup ; Öztürk, Ömer ; Kacar, Sabite</creatorcontrib><description>Background
In chronic Hepatitis B virus (HBV) infection, certain individual and viral characteristics such as advanced age, presence of hepatic steatosis (HS), normal ALT levels, initially negative HBeAg and HBV DNA, and genotype of the virus are associated with HBsAg seroclearance and seroconversion. Herein, we report the results of our study evaluating the association between hepatosteatosis and HbsAg seroconversion.
Methods
The clinical and biochemical data of patients with CHB and hepatosteatosis (HS) (HBsAg seroconversion, n:52, and non‐HbsAg seroconversion, n:352), and the rate of development of HBsAg seroconversion were evaluated.
Results
We collected data from 404 patients with HBeAg negative CBH (mean age ± SD: 36.2 ± 11 years; 223 [55.2%] men, 181 [44.8%] women). The mean age at diagnosis of disease was 36.2 ± 11 years. The mean duration of the disease was 10.6 ± 7 years. Seroconversion developed in 52 patients (12.8%) with serum HBsAg positive (mean ± SD: 12.7 ± 5.8). Elderly age and the duration of disease time were significantly associated with seroconversion (P < .001).
The presence of serum HBsAg seroconversion was significantly associated with hepatosteatosis (OR: 3.06, 95% CI 1.64‐5.71, P < .01). Serum HBsAg seroconversion was more frequent in patients with mild HS than patients with moderate‐severe HS (P = .04). In multivariate regression analysis, the presence of HS was found to be an independent factor predicting the development of HBsAg seroconversion (OR: 2.07 95% GA:1.07‐4.0 P = .03).
Conclusion
The presence of mild HS in HBeAg negative chronic hepatitis B patients contributes to HBsAg seroconversion. Further studies are required to better understand the relationship between steatosis and HBsAg seroconversion.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.14899</identifier><identifier>PMID: 34547163</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Age ; Aged ; Chronic infection ; Fatty liver ; Female ; Genotypes ; Hepatitis B ; Hepatitis B e antigen ; Hepatitis B e Antigens ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens ; Hepatitis B, Chronic ; Humans ; Interferon ; Male ; Patients ; Seroconversion ; Steatosis</subject><ispartof>International journal of clinical practice (Esher), 2021-12, Vol.75 (12), p.e14899-n/a</ispartof><rights>2021 John Wiley & Sons Ltd</rights><rights>2021 John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3939-171034950af420000ac50fa9c57e029c77bac79379c6da801dd40ef1206681313</citedby><cites>FETCH-LOGICAL-c3939-171034950af420000ac50fa9c57e029c77bac79379c6da801dd40ef1206681313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.14899$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.14899$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34547163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bacaksız, Ferhat</creatorcontrib><creatorcontrib>Gökcan, Hale</creatorcontrib><creatorcontrib>Akdoğan, Meral</creatorcontrib><creatorcontrib>Gökçe, Dilara Turan</creatorcontrib><creatorcontrib>Arı, Derya</creatorcontrib><creatorcontrib>Gökbulut, Volkan</creatorcontrib><creatorcontrib>Ergün, Yakup</creatorcontrib><creatorcontrib>Öztürk, Ömer</creatorcontrib><creatorcontrib>Kacar, Sabite</creatorcontrib><title>Role of hepatosteatosis in HBsAg seroconversion in HBeAg‐negative chronic hepatitis B patients</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Background
In chronic Hepatitis B virus (HBV) infection, certain individual and viral characteristics such as advanced age, presence of hepatic steatosis (HS), normal ALT levels, initially negative HBeAg and HBV DNA, and genotype of the virus are associated with HBsAg seroclearance and seroconversion. Herein, we report the results of our study evaluating the association between hepatosteatosis and HbsAg seroconversion.
Methods
The clinical and biochemical data of patients with CHB and hepatosteatosis (HS) (HBsAg seroconversion, n:52, and non‐HbsAg seroconversion, n:352), and the rate of development of HBsAg seroconversion were evaluated.
Results
We collected data from 404 patients with HBeAg negative CBH (mean age ± SD: 36.2 ± 11 years; 223 [55.2%] men, 181 [44.8%] women). The mean age at diagnosis of disease was 36.2 ± 11 years. The mean duration of the disease was 10.6 ± 7 years. Seroconversion developed in 52 patients (12.8%) with serum HBsAg positive (mean ± SD: 12.7 ± 5.8). Elderly age and the duration of disease time were significantly associated with seroconversion (P < .001).
The presence of serum HBsAg seroconversion was significantly associated with hepatosteatosis (OR: 3.06, 95% CI 1.64‐5.71, P < .01). Serum HBsAg seroconversion was more frequent in patients with mild HS than patients with moderate‐severe HS (P = .04). In multivariate regression analysis, the presence of HS was found to be an independent factor predicting the development of HBsAg seroconversion (OR: 2.07 95% GA:1.07‐4.0 P = .03).
Conclusion
The presence of mild HS in HBeAg negative chronic hepatitis B patients contributes to HBsAg seroconversion. Further studies are required to better understand the relationship between steatosis and HBsAg seroconversion.</description><subject>Age</subject><subject>Aged</subject><subject>Chronic infection</subject><subject>Fatty liver</subject><subject>Female</subject><subject>Genotypes</subject><subject>Hepatitis B</subject><subject>Hepatitis B e antigen</subject><subject>Hepatitis B e Antigens</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens</subject><subject>Hepatitis B, Chronic</subject><subject>Humans</subject><subject>Interferon</subject><subject>Male</subject><subject>Patients</subject><subject>Seroconversion</subject><subject>Steatosis</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1OGzEQxy1URID2wgNUK3GpkBY8_livjyFq-RASqGrPrnFmE0ebdWpvqLjxCDwjT4LDAgcOncN4NPr5p9GfkAOgx5DrxC_c6hhErfUW2QUlWAlMwKc886ouJeUwInspLShlUtZ0h4y4kEJBxXfJn5-hxSI0xRxXtg-px033qfBdcX6axrMiYQwudHcYkw_dsMfx7OnhscOZ7f0dFm4eQ-fd4PB9_n1abCbs-vSZbDe2Tfjl9d0nv398_zU5L6-uzy4m46vScc11CQooF1pS2whGc1knaWO1kwop006pW-uU5kq7amprCtOpoNgAo1VVAwe-T74N3lUMf9eYerP0yWHb2g7DOhkmleQ1q2qW0cMP6CKsY5evM6wCobNP1pk6GigXQ0oRG7OKfmnjvQFqNrmbTe7mJfcMf31Vrm-XOH1H34LOAAzAP9_i_X9U5uJycjNInwEz64z7</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Bacaksız, Ferhat</creator><creator>Gökcan, Hale</creator><creator>Akdoğan, Meral</creator><creator>Gökçe, Dilara Turan</creator><creator>Arı, Derya</creator><creator>Gökbulut, Volkan</creator><creator>Ergün, Yakup</creator><creator>Öztürk, Ömer</creator><creator>Kacar, Sabite</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Role of hepatosteatosis in HBsAg seroconversion in HBeAg‐negative chronic hepatitis B patients</title><author>Bacaksız, Ferhat ; Gökcan, Hale ; Akdoğan, Meral ; Gökçe, Dilara Turan ; Arı, Derya ; Gökbulut, Volkan ; Ergün, Yakup ; Öztürk, Ömer ; Kacar, Sabite</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3939-171034950af420000ac50fa9c57e029c77bac79379c6da801dd40ef1206681313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Aged</topic><topic>Chronic infection</topic><topic>Fatty liver</topic><topic>Female</topic><topic>Genotypes</topic><topic>Hepatitis B</topic><topic>Hepatitis B e antigen</topic><topic>Hepatitis B e Antigens</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens</topic><topic>Hepatitis B, Chronic</topic><topic>Humans</topic><topic>Interferon</topic><topic>Male</topic><topic>Patients</topic><topic>Seroconversion</topic><topic>Steatosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bacaksız, Ferhat</creatorcontrib><creatorcontrib>Gökcan, Hale</creatorcontrib><creatorcontrib>Akdoğan, Meral</creatorcontrib><creatorcontrib>Gökçe, Dilara Turan</creatorcontrib><creatorcontrib>Arı, Derya</creatorcontrib><creatorcontrib>Gökbulut, Volkan</creatorcontrib><creatorcontrib>Ergün, Yakup</creatorcontrib><creatorcontrib>Öztürk, Ömer</creatorcontrib><creatorcontrib>Kacar, Sabite</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bacaksız, Ferhat</au><au>Gökcan, Hale</au><au>Akdoğan, Meral</au><au>Gökçe, Dilara Turan</au><au>Arı, Derya</au><au>Gökbulut, Volkan</au><au>Ergün, Yakup</au><au>Öztürk, Ömer</au><au>Kacar, Sabite</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of hepatosteatosis in HBsAg seroconversion in HBeAg‐negative chronic hepatitis B patients</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2021-12</date><risdate>2021</risdate><volume>75</volume><issue>12</issue><spage>e14899</spage><epage>n/a</epage><pages>e14899-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Background
In chronic Hepatitis B virus (HBV) infection, certain individual and viral characteristics such as advanced age, presence of hepatic steatosis (HS), normal ALT levels, initially negative HBeAg and HBV DNA, and genotype of the virus are associated with HBsAg seroclearance and seroconversion. Herein, we report the results of our study evaluating the association between hepatosteatosis and HbsAg seroconversion.
Methods
The clinical and biochemical data of patients with CHB and hepatosteatosis (HS) (HBsAg seroconversion, n:52, and non‐HbsAg seroconversion, n:352), and the rate of development of HBsAg seroconversion were evaluated.
Results
We collected data from 404 patients with HBeAg negative CBH (mean age ± SD: 36.2 ± 11 years; 223 [55.2%] men, 181 [44.8%] women). The mean age at diagnosis of disease was 36.2 ± 11 years. The mean duration of the disease was 10.6 ± 7 years. Seroconversion developed in 52 patients (12.8%) with serum HBsAg positive (mean ± SD: 12.7 ± 5.8). Elderly age and the duration of disease time were significantly associated with seroconversion (P < .001).
The presence of serum HBsAg seroconversion was significantly associated with hepatosteatosis (OR: 3.06, 95% CI 1.64‐5.71, P < .01). Serum HBsAg seroconversion was more frequent in patients with mild HS than patients with moderate‐severe HS (P = .04). In multivariate regression analysis, the presence of HS was found to be an independent factor predicting the development of HBsAg seroconversion (OR: 2.07 95% GA:1.07‐4.0 P = .03).
Conclusion
The presence of mild HS in HBeAg negative chronic hepatitis B patients contributes to HBsAg seroconversion. Further studies are required to better understand the relationship between steatosis and HBsAg seroconversion.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>34547163</pmid><doi>10.1111/ijcp.14899</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2021-12, Vol.75 (12), p.e14899-n/a |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2575382682 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Age Aged Chronic infection Fatty liver Female Genotypes Hepatitis B Hepatitis B e antigen Hepatitis B e Antigens Hepatitis B surface antigen Hepatitis B Surface Antigens Hepatitis B, Chronic Humans Interferon Male Patients Seroconversion Steatosis |
| title | Role of hepatosteatosis in HBsAg seroconversion in HBeAg‐negative chronic hepatitis B patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A12%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20hepatosteatosis%20in%20HBsAg%20seroconversion%20in%20HBeAg%E2%80%90negative%20chronic%20hepatitis%20B%20patients&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Bacaks%C4%B1z,%20Ferhat&rft.date=2021-12&rft.volume=75&rft.issue=12&rft.spage=e14899&rft.epage=n/a&rft.pages=e14899-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.14899&rft_dat=%3Cproquest_cross%3E2575382682%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2614981358&rft_id=info:pmid/34547163&rfr_iscdi=true |